7.01

8.72% -0.67

After Hours: 6.80 -0.21 -3.00%

Silence Therapeutics Plc Adr (SLN)

Overview News Price History Discussions Forecast

Silence Therapeutics Plc Adr stock is traded at $7.01, with a volume of 1.49M. It is down -8.72% in the last 24 hours and down -61.06% over the past month. Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Previous Close:

$7.68

Open:

$7.76

24h Volume:

1.49M

Relative Volume:

4.89

Market Cap:

$330.98M

Revenue:

$31.37M

Net Income/Loss:

$-53.77M

P/E Ratio:

-4.9255

EPS:

-1.4232

Net Cash Flow:

$-49.02M

1W Performance:

-44.80%

1M Performance:

-61.06%

6M Performance:

-69.81%

1Y Performance:

-39.31%

1-Day Range:

$6.95

$8.74

1-Week Range:

$5.81

$12.80

52-Week Range:

$5.81

$27.72

Silence Therapeutics Plc Adr Stock (SLN) Company Profile

Name

Silence Therapeutics Plc Adr

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

Address

Employee

109

Twitter

Next Earnings Date

Latest SEC Filings

SLN's Discussions on Twitter

Compare SLN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLN	7.01	330.98M	31.37M	-53.77M	-49.02M	-1.4232
VRTX	450.97	116.14B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	81.10B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.23B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.12B	3.30B	-501.07M	1.03B	11.54

Silence Therapeutics Plc Adr Stock (SLN) Latest News

Nov 20, 2024

SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Yahoo Finance

Nov 20, 2024

GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Yahoo Finance

Nov 20, 2024

United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India

Nov 20, 2024

Nov 19, 2024

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com

Nov 19, 2024

Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks

Nov 19, 2024

SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks

Nov 19, 2024

Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga

Nov 19, 2024

Nov 17, 2024

Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 17, 2024

Oct 21, 2024

Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance

Oct 21, 2024

Oct 16, 2024

80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港

Oct 16, 2024

Oct 01, 2024

ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance

Oct 01, 2024

Sep 30, 2024

Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine By Investing.com - Investing.com South Africa

Sep 30, 2024

Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine - Investing.com

Sep 30, 2024

Sep 25, 2024

Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance

Sep 25, 2024

Sep 24, 2024

CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease - Yahoo Finance

Sep 24, 2024

Sep 02, 2024

It makes sense and dollars to buy Silence Therapeutics Plc ADR (SLN) stock - SETE News

Sep 02, 2024